HCA Healthcare, Inc.
NYSE:HCAMedical - Care Facilities
-$12.05 today
- Market cap
- $99.51B
- Beta
- 1.13
- P/E (TTM)
- 12.5
- EPS (TTM)
- $29.98
- Dividend yield
- 0.80%
Volume 1.60M
Average 1.37M
HCA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
HCA Healthcare, Inc.NYSE: HCA
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2026 EBITDA of $4.01B rose 4.3% year over year, behind the +10.3% change in trailing-twelve-month EBITDA. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.
Context
- EBITDA amounted to 20.6% of revenue in FY2025, up 1.0 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 18 analysts of $16.09B (+3.1%) for the fiscal year ending Dec 2026, a slowdown from the +12.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $4.01B+5.5% QoQ
- Last fiscal yearDec 2025
- $15.6B+12.3% YoY
- LTMJun 2026
- $15.84B+10.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.3% | -4.9% | -9.2 pp |
| 1 year | +12.3% | +3.1% | -9.2 pp |
| 3-year CAGR | +5.5% | +5.8% | +0.3 pp |
| 5-year CAGR | +7.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 15.6B USD
- Year-over-year change
- +12.3%
- 4-year CAGR
- +2.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.6B | +12.3% |
| FY2024 | 2024-12-31 | 13.9B | +9.2% |
| FY2023 | 2023-12-31 | 12.72B | -4.3% |
| FY2022 | 2022-12-31 | 13.29B | -6.7% |
| FY2021 | 2021-12-31 | 14.25B | — |
EBITDA vs competitors
How HCA compares with its peers on the latest reported figures
- HCA's LTM Jun 2026 EBITDA of $15.84B is the highest of the 6 companies compared; the peer median is $2.82B.
- Its year-over-year change of +10.3% is the 4th highest of 6, against a peer median of +16.2%.
- EBITDA amounts to 20.3% of revenue for HCA, versus a peer median of 15.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $15.84B | +10.3% | +5.5% | 20.3% | |
| LTM Jun 2026 | $5.06B | +9.6% | +13.4% | 23.2% | |
| LTM Mar 2026 | $4.96B | +296.6% | +20.0% | 23.1% | |
| LTM Jun 2026 | $2.82B | +16.2% | +20.3% | 15.6% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $505.76M | -10.5% | -2.2% | 7.9% |
| LTM Jun 2026 | $480.11M | +62.7% | +12.8% | 8.6% | |
| Peer median (excluding HCA) | $2.82B | +16.2% | +13.4% | 15.6% | |
Competitors are the stored peer set for HCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 58.75B | 60.23B | 64.97B | 70.6B | 75.6B |
| Cost of Revenue | 36.26B | 37.06B | 39.39B | 41.93B | 44.23B |
| Gross Profit | 22.49B | 23.18B | 25.58B | 28.68B | 31.37B |
| Gross Margin | 38.3% | 38.5% | 39.4% | 40.6% | 41.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 26.78B | 27.69B | 29.49B | 31.17B | 8B |
| Operating Expenses | 12.81B | 14.12B | 15.95B | 18.13B | 19.41B |
| Depreciation & Amortization | 2.85B | 2.97B | 3.08B | 3.31B | 3.52B |
| EBITDA | 14.25B | 13.29B | 12.72B | 13.9B | 15.6B |
| EBITDA Margin | 24.3% | 22.1% | 19.6% | 19.7% | 20.6% |
| Operating Income | 9.68B | 9.05B | 9.63B | 10.55B | 11.97B |
| Operating Margin | 16.5% | 15.0% | 14.8% | 14.9% | 15.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.53B | 1.74B | 1.94B | 2.06B | 2.25B |
| Other Income / Expenses | 155M | (473M) | (1.92B) | (2.02B) | (2.13B) |
| Income Before Tax | 9.83B | 8.58B | 7.71B | 8.52B | 9.83B |
| Pre-Tax Margin | 16.7% | 14.2% | 11.9% | 12.1% | 13.0% |
| Income Tax Expense | 2.11B | 1.75B | 1.62B | 1.87B | 2.05B |
| Net Income | 6.96B | 5.64B | 5.24B | 5.76B | 6.78B |
| Net Margin | 11.8% | 9.4% | 8.1% | 8.2% | 9.0% |
| EPS (Basic) | 21.51 | 19.44 | 19.24 | 22.27 | 28.62 |
| EPS (Diluted) | 21.16 | 19.15 | 18.96 | 22.00 | 28.38 |
| Weighted Avg Shares | 323.32M | 290.35M | 272.4M | 258.6M | 230.71M |
| Weighted Avg Shares (Diluted) | 328.75M | 294.67M | 276.41M | 261.81M | 230.71M |
HCA Healthcare, Inc.
NYSE:HCA
Intrinsic Alpha fair value
Locked
Current Price
$476.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.